» Articles » PMID: 34829429

β-Defensin 2, an Antimicrobial Peptide, As a Novel Biomarker for Ulcerative Interstitial Cystitis; Can β-Defensin 2 Suspect the Dysbiosis of Urine Microbiota?

Overview
Specialty Radiology
Date 2021 Nov 27
PMID 34829429
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

As urine is not sterile, inflammatory reactions caused by dysbiosis of the urinary microbiota may induce interstitial cystitis. A study was conducted to determine whether β-defensin 2 (BD-2), a specific antimicrobial peptide in the bladder, could be used as a novel diagnostic marker for ulcerative interstitial cystitis (IC). Urine samples from three female groups were examined: healthy controls ( = 34, Control group), non-Hunner type IC ( = 40, NHIC group), and Hunner type IC ( = 68, HIC group). Urine samples were collected via a transurethral catheter and assayed for BD-2 levels using enzyme linked immunosorbent assay. Under general or regional anesthesia, cystoscopy with diagnostic and therapeutic hydrodistension was performed in NHIC and HIC groups patients. These patients underwent a biopsy of the bladders. Based on the urinary specimens from 142 patients, BD-2 expression was found to be 18-fold higher in patients with Hunner type IC than in patients with non-Hunner type IC. The enhanced secretion of BD-2 exhibited a strong correlation with increased mast cell counts associated with bladder IC pathology. Enhanced urinary secretion of the antimicrobial peptide BD-2 from Hunner type IC patients associated with clinical phenotypes and demonstrated relatively robust levels to be used as a potential biomarker. Moreover, the increased urinary level of BD-2 may suggest a new possibility of biomarkers caused by dysbiosis of the urinary microbiota in ulcerative IC.

Citing Articles

Untargeted Metabolomics Pilot Study Using UHPLC-qTOF MS Profile in Sows' Urine Reveals Metabolites of Bladder Inflammation.

Pousinis P, Virgiliou C, Mouskeftara T, Chalvatzi S, Kroustallas F, Panteris E Metabolites. 2022; 12(12).

PMID: 36557224 PMC: 9784506. DOI: 10.3390/metabo12121186.


Editorial: Special Issue "Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)".

Neuhaus J, Gonsior A, Berndt-Paetz M Diagnostics (Basel). 2022; 12(7).

PMID: 35885593 PMC: 9317840. DOI: 10.3390/diagnostics12071689.

References
1.
Yadava P, Zhang C, Sun J, Hughes J . Antimicrobial activities of human beta-defensins against Bacillus species. Int J Antimicrob Agents. 2006; 28(2):132-7. DOI: 10.1016/j.ijantimicag.2006.02.021. View

2.
Brubaker L, Wolfe A . The urinary microbiota: a paradigm shift for bladder disorders?. Curr Opin Obstet Gynecol. 2016; 28(5):407-12. PMC: 5378062. DOI: 10.1097/GCO.0000000000000298. View

3.
Alhagamhmad M, Day A, Lemberg D, Leach S . An overview of the bacterial contribution to Crohn disease pathogenesis. J Med Microbiol. 2016; 65(10):1049-1059. DOI: 10.1099/jmm.0.000331. View

4.
Yoo J, Shin H, Song J, Kim M, Yun J, Kim Z . Urinary Microbiome Characteristics in Female Patients with Acute Uncomplicated Cystitis and Recurrent Cystitis. J Clin Med. 2021; 10(5). PMC: 7961880. DOI: 10.3390/jcm10051097. View

5.
Kogan M, Naboka Y, Ibishev K, Gudima I, Naber K . Human urine is not sterile - shift of paradigm. Urol Int. 2015; 94(4):445-52. DOI: 10.1159/000369631. View